Preventing and limiting minimal residual disease following targeted cancer therapy

Bidragets beskrivning

While targeted therapy has transformed the treatment of cancer, the long-term efficacy of these strategies is severely compromized by drug resistance. In the center stage of this process is the ability of some cancer cells to adapt to drug treatment and lay dormant for long period of time. Clinically this phenomenon is observed as minimal residual disease in most patients treated with targeted therapies. The aim of this reserach is to investigate the means cancer cells use to adapt to drug treatment and understand how residual tumor cells modulate the immune system during residual disease. The ultimate goal is to identify vulnerabilities in residual cancer cells, or in the mechanisms that allow the establishment of residual disease, in order to develop combination treatments that will prevent residual disease. This could significantly improve the long-term efficacy of cancer treatments.
Visa mer

Startår

2021

Slutår

2026

Beviljade finansiering

Kari Kurppa Orcid -palvelun logo
447 650 €

Andra beslut

361970
Akademiforskarens forskningskostnader(2024)
199 465 €
346656
Akademiforskarens forskningskostnader(2021)
300 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Övriga uppgifter

Finansieringsbeslutets nummer

338466

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

cancer